Population health & analytics · Population health services
Syra Health
Syra Health is a publicly traded healthcare company whose population health unit provides analytics and related services to government and community health programs.
Strong fit
- State and community programs that need population health analytics and related services from a company with public financial reports
- Buyers who will track program results and whether the contract is delivered after go-live
- Teams comparing smaller, publicly traded population health companies
Weak fit
- Hospitals buying operating room capacity tools, such as LeanTaaS
- Community health centers that only need a small analytics dashboard with no services
- Groups shopping for an EHR
Bottom line
Syra Health is worth considering for government and community health programs that want a smaller population health analytics and services vendor whose finances are publicly reported. It suits buyers who will track whether its programs move contract measures. Buyers who want an enterprise value-based care suite may prefer Lightbeam or Persivia.
Score breakdown
Weights: Outcomes 35% · Product 30% · Implementation 20% · Pricing clarity 15%.
Syra Health is a publicly traded healthcare company, and its population health unit provides analytics and related services for state and community health programs. Because it files financial reports with the SEC, its results by business unit are public, unlike those of most private ACO platforms, and the population health unit has grown sharply. Gregory Alexander became CEO in early 2026 after earlier leadership changes. Contracts are custom and combine software with services.
Results depend on whether the program work and analytics move contract measures. Syra is narrower than the large value-based care suites from Lightbeam and Persivia, and different from Azara's quality tools for community health centers. Among the population health tools we review, it scores 7.4 overall, level with Persivia and behind Azara (7.6) and Cozeva (7.5). Azara suits quality work at community health centers, and Olio suits post-acute care coordination.
Competitor landscape
| Vendor | Overall | Ease of implementation |
|---|---|---|
| Azara Healthcare | 7.6 | 7.2 |
| Cozeva | 7.5 | 7.2 |
| Persivia | 7.4 | 7.1 |
| Syra Health | 7.4 | 7.1 |
| Certilytics | 7.3 | 7.0 |
| Trella Health | 7.3 | 7.0 |
| IMAT Solutions | 7.0 | 6.7 |
| Elligint Health | 6.9 | 6.6 |
| Olio | 6.9 | 6.7 |
| Lightbeam Health Solutions | 6.8 | 6.5 |
| Relevant Healthcare | 6.8 | 6.6 |
| Hexplora | 6.7 | 6.5 |
Pricing
| Item | Detail |
|---|---|
| Model | Custom population health analytics and services contracts. As a public company, it files financial reports with the SEC. |
| What usually drives cost | Program scope, analytics modules, and consulting services. |
| What to ask before you buy | Contract cost for your population and which deliverables are software and which are services. |
| Published pricing | Quoted for each contract. Syra Health's SEC filings report results by business unit. |
Syra Health's SEC filings break out results for its population health unit.
Prerequisites for purchase
| Need | Why it matters |
|---|---|
| What you need to get Syra Health to function | |
| A named population health or quality owner who can direct care gap work | Someone has to turn the dashboards into care gap work. |
| A clear definition of which patients count, agreed with finance | If finance and the program count patients differently, savings cannot be agreed. |
| A list of EHR, claims, and admission and discharge alert feeds | Each missing feed leaves part of the population out of view. |
| Care managers or partners with time to follow up on lists | Patients on a list benefit only when someone reaches them. |
| Contract measures chosen before kickoff | A target that changes midway makes the early work hard to judge. |
| What will maximize your value | |
| Track closed gaps, readmissions, or use of services every week for 90 days | Those measures show whether care changed. |
| Start with one patient group or partner network | A single group gives early, clear evidence before the program grows. |
| Drop duplicate spreadsheet lists after a month of running both | Two parallel lists double the data entry. |
| Review high-risk or transferring patients nobody has reached in a regular huddle | Patients nobody has reached are easy to lose without a standing review. |
| Send a quarterly results summary to clinical leaders | Regular reporting brings backlogs to leaders early. |
| Deal-breakers | |
| You have no value-based, quality, or post-acute program to act on. | |
| Nobody will own follow-up work. | |
| You refuse any EHR or claims data sharing. | |
| You expect a population health tool to replace your EHR. | |
| Leaders will not measure results. | |
Value creation time frame
| # | Stage | Typical range |
|---|---|---|
| 1 | Plan and data | 4-8 weeks to define patients, data feeds, and success measures. |
| 2 | Connect | 2-4 months to connect claims, EHR, and admission alerts, then check the data. |
| 3 | Pilot | 1-2 months with one contract, site, or group of partners. |
| 4 | Expand | Ongoing: more patients and fine-tuning of care work. |
Leadership
Methodology
| Weight | Factor | What it measures |
|---|---|---|
| 35% | Customer outcomes | Whether buyers get measurable operational or clinical-workflow results after go-live |
| 30% | Product | Capability depth, reliability, and fit for the job the category buys |
| 20% | Implementation | How hard it is to stand up, integrate, train, and stabilize |
| 15% | Pricing clarity | Whether a buyer can model total cost without a mystery quote |
| Label | Meaning |
|---|---|
| Highly recommend | Strong outcomes and product with manageable caveats |
| Recommend | Solid fit for the right buyer; know the tradeoffs |
| Conditional | Only with a specific use case or heavy caveats |
| Not recommended | Avoid for most buyers in this category |
Read our full methodology for how we weight scores and assign recommend labels.